Cost-effectiveness Analysis of Two Regimens in the Treatment of Chronic Hepatitis B Fibrosis / 中国药房
China Pharmacy
;
(12): 4899-4901, 2015.
Article
in Chinese
| WPRIM
| ID: wpr-501270
ABSTRACT
OBJECTIVE:
To analyze the cost-effectiveness of two regimens in the treatment of chronic hepatitis B fibrosis.METHODS:
112 cases of chronic hepatitis B fibrosis were divided into Compound biejia ruangan tablet group (group A,n=56) and Anluo huaxian pill group(group B,n=56). Both groups received Entecavir dispersible tablets combined with relevant Chinese patent medicine. The liver fibrosis index and transient elastography of 2 group were detected before and after treatment,TCM symp-tom score and effective rate calculation were conducted to compare the cost-effectiveness of 2 groups.RESULTS:
The cost,effec-tive rate and cost-effectiveness ratio of group A were 9 227.10 yuan,74.11% and 12 451;those of group B were 8 202.90 yuan, 69.28%and 11 840;incremental cost-effectiveness ratio was 21 205. Group B showed a better cost-effectiveness. Result of sensitiv-ity test was same to that of cost-effectiveness analysis.CONCLUSIONS:
The cost-effectiveness of Anluo huaxian pill combined with Entecavir dispersible tables is better than Compound biejia ruangan tablet combined with Entecavir dispersible tables in the treatment of chronic hepatitis B fibrosis.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Health economic evaluation
Language:
Chinese
Journal:
China Pharmacy
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS